Cingulate Q3 EPS Reduced by Ascendiant Capital Markets

Key Points

• Ascendiant Capital Markets cut Cingulate’s Q3 2026 EPS forecast to a loss of $0.39 per share from a prior estimate of $0.33, while maintaining a “Buy” rating and a $52 price target.
• Analyst sentiment remains mixed but leans positive: Cingulate has an average “Moderate Buy” rating and a $27 consensus price target, based on three Buy ratings and one Sell rating.
• Cingulate reported a quarterly loss of $0.45 per share, beating the consensus estimate of a $0.63 loss. Institutional investors own approximately 41.3% of the company.

Cingulate Inc. (NASDAQ:CING - Free Report) - Equities research analysts at Ascendiant Capital Markets reduced their Q3 2026 earnings per share estimates for Cingulate in a report issued on Wednesday, August 19th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($0.39) per share for the quarter, down from their prior estimate of ($0.33). Ascendiant Capital Markets has a "Buy" rating and a $52.00 price target on the stock. The consensus estimate for Cingulate's current full-year earnings is ($2.39) per share. Ascendiant Capital Markets also issued estimates for Cingulate's Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.04) EPS, Q1 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.29) EPS and FY2027 earnings at ($1.38) EPS.

Several other research analysts have also weighed in on the stock. Roth Capital set a $9.00 price objective on shares of Cingulate and gave the stock a "buy" rating in a research note on Sunday. Wall Street Zen raised shares of Cingulate from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Cingulate in a report on Tuesday, May 26th. Finally, Weiss Ratings cut shares of Cingulate from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 18th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cingulate has an average rating of "Moderate Buy" and an average price target of $27.00.

Cingulate Price Performance

Shares of NASDAQ:CING opened at $5.68 on Tuesday. The company has a market capitalization of $82.60 million, a price-to-earnings ratio of -1.58 and a beta of -0.90. The firm's 50 day simple moving average is $4.99 and its 200 day simple moving average is $5.57. Cingulate has a fifty-two week low of $3.16 and a fifty-two week high of $11.89.

Cingulate (NASDAQ:CING - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.18.

Hedge Funds Weigh In On Cingulate

Several institutional investors have recently modified their holdings of CING. XTX Topco Ltd bought a new stake in Cingulate during the 4th quarter worth approximately $90,000. Quadrature Capital Ltd bought a new position in Cingulate in the fourth quarter valued at approximately $66,000. Kestra Advisory Services LLC lifted its stake in Cingulate by 29.8% in the fourth quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company's stock valued at $529,000 after buying an additional 27,979 shares in the last quarter. DRW Securities LLC acquired a new position in shares of Cingulate in the fourth quarter valued at approximately $255,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Cingulate by 43.9% in the fourth quarter. Geode Capital Management LLC now owns 61,035 shares of the company's stock valued at $265,000 after buying an additional 18,629 shares during the period. Institutional investors own 41.31% of the company's stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source